What Are Biosimilars? Biologics, Regulatory Approval & Totality of Evidence Explained скачать в хорошем качестве

What Are Biosimilars? Biologics, Regulatory Approval & Totality of Evidence Explained

What Are Biosimilars? And why are they reshaping the future of Biologics and Healthcare Business? In this session from Ramadan Regulatory Series 2026, we break down the real science and regulatory logic behind Biosimilars — beyond surface definitions. This lecture covers: • الفرق بين Biologics و Small Molecules • لماذا لا يمكن إثبات Identity في البيوسيميلار • مفهوم Similarity مقابل Generic • Totality of Evidence Framework • Analytical Similarity & PK/PD Bridging • Immunogenicity Risk and its regulatory impact • Manufacturing complexity in recombinant DNA products • Why Phase III is no longer the sole decision driver • Regulatory Strategy & Market Access implications We also discuss how global regulatory trends (FDA, EMA) are shifting toward risk-based evaluation and analytical-driven approvals — and what this means for emerging markets and the Arab region. This video is essential for: Regulatory Affairs professionals Pharma executives Healthcare strategists Biologics manufacturers Anyone entering the Biosimilar space Biosimilars are not just lower-cost alternatives. They represent a structural shift in Biologics development, approval, and market positioning. 🔔 Subscribe for more insights on: Biologics Biosimilars Regulatory Strategy Totality of Evidence Healthcare Business Trends #Biosimilars #Biologics #RegulatoryStrategy #TotalityOfEvidence #Immunogenicity #PharmaLeadership #HealthcareBusiness